ulifloxacin

structure given in first source

Also Known As:

6-fluoro-1-methyl-7-(1-piperazinyl)-4-oxo-4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid; NM 394; NM-394; NM394; 1H,4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-

Networked: 19 relevant articles (3 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - ulifloxacin: 19
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        ulifloxacin: 19

Experts

1.	Picollo, Rossella: 4 articles (09/2018 - 01/2007)
2.	Dionisio, Paolo: 4 articles (02/2012 - 01/2005)
3.	Ruggieri, Alessandro: 3 articles (02/2012 - 01/2007)
4.	Passali, Desiderio: 2 articles (12/2015 - 02/2012)
5.	Rosignoli, Maria Teresa: 2 articles (02/2012 - 01/2007)
6.	Kurosawa, Tohru: 2 articles (06/2009 - 02/2004)
7.	Barattè, Simona: 2 articles (01/2009 - 01/2007)
8.	Ammendola, Marco: 1 article (09/2018)
9.	Comandini, Alessandro: 1 article (09/2018)
10.	Coppola, Paola: 1 article (09/2018)

Related Diseases

1.	Infections 12/01/1996 - "In conclusion, prulifloxacin (NM394) showed potent antibacterial activity against clinical isolates and potent therapeutic efficacy against experimental infection in spite of its lower AUCs compared with the reference drugs. " 01/01/2009 - "These findings confirm the ability of prulifloxacin to penetrate prostatic tissues, indicating high exposure of the target tissue to ulifloxacin and, therefore, a potential therapeutic role for prulifloxacin in the treatment of bacterial prostatic infections." 01/01/2006 - "In conclusion, the in vitro inhibitory and bactericidal activities exhibited by ulifloxacin and the favorable characteristics shown by its prodrug (prulifloxacin) in clinical trials, particularly indicate this drug for the treatment of lung and urinary infections."
2.	Bacterial Infections (Bacterial Infection) 01/01/2007 - "Tissue concentrations observed after repeated administrations were generally higher than the ulifloxacin minimum inhibitory concentrations for pathogens more frequently involved in gynaecological bacterial infections. " 03/01/1996 - "These results suggest that uptake of NM394 by human polymorphonuclear leukocytes occurs via an active transport system differing from that of ofloxacin, whose uptake is affected by the presence of L-glycine and L-leucine, and that once accumulated, NM394 remains intracellularly active and participates in protection against bacterial infection."
3.	Pneumonia (Pneumonitis) 06/01/2009 - "Ulifloxacin is a new quinolone antibiotic and it is effective against pneumonia. "
4.	Cardiac Arrhythmias (Arrythmia) 12/01/2015 - "Ulifloxacin T(1/2) and plasma and tissue concentrations including the nose-paranasal sinuses mucosa allow once daily administration at the dosage of 600 mg. Prulifloxacin shows a high safety profile: it is the fluoroquinolone with the lowest risk of cardiac arrhythmias for prolongation of the QT interval; the CNS penetration is negligible; in women prulifloxacin does not affect the lactobacillary component of the vaginal microbiota, lowering the risk of genito-urinary tract infections. " 02/01/2004 - "In this in vivo study using a rabbit arrhythmia model, we assessed the proarrhythmic effects and changes in the QT interval elicited by the administration of NM394 (UFX), an active metabolite of the new quinolone antibiotic prulifloxacin, and three representative quinolones, sparfloxacin (SPFX), gatifloxacin (GFLX) and levofloxacin (LVFX). "
5.	Rhinosinusitis 02/01/2012 - "The aim of this study was to assess the concentration of ulifloxacin, the active metabolite of prulifloxacin, in sinuses mucosa and plasma of patients with chronic rhinosinusitis, requiring sinus elective endoscopic surgery. " 09/01/2018 - "The antibacterial agent prulifloxacin, a prodrug of ulifloxacin, is indicated in the treatment of acute lower urinary tract infections, acute exacerbation of chronic bronchitis and acute bacterial rhinosinusitis. "

Related Drugs and Biologics

1.	prulifloxacin
2.	Anti-Bacterial Agents (Antibiotics)
3.	Quinolones
4.	Ofloxacin (Ofloxacine)
5.	Leucine (L-Leucine)
6.	Glycine (Aminoacetic Acid)
7.	Fluoroquinolones
8.	Proteins (Proteins, Gene)
9.	Prodrugs
10.	Levofloxacin (Levaquin)